Anna Chiara De Luca
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anna Chiara De Luca has a total of 347 co-authors. Here are the top co-authors by number of shared publications:
- Stefano Managò
National Research Council (Italy)
28 shared publications - Michael Mazilu
SUPA, School of Physics and Astronomy, University of St. Andrews, St. Andrews KY16 9SS, UK
19 shared publications - Maria Antonietta Ferrara
Institute of Applied Sciences and Intelligent Systems, Unit of Naples, Italian National Research Council (ISASI-CNR), Via Pietro Castellino 111, 80131 Napoli, Italy
18 shared publications - Giulia Rusciano
Department of Physics “E. Pancini”, University of Naples “Federico II”, 80126 Naples, Italy
17 shared publications - Kishan Dholakia
Centre of Light for Life, School of Biological Sciences, Adelaide University, Adelaide, Australia
17 shared publications - Antonio Sasso
Department of Physics “E. Pancini”, University of Naples “Federico II”, 80126 Naples, Italy
16 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Integrated Raman Spectroscopy and Supervised Imaging for Label-Free Identification and Mapping of Oral Pathogens in Complex Biofilms
Although Raman spectroscopy has demonstrated excellent performance for the identification of isolated bacterial cells, its application to spatially resolved analysis of complex polymicrobial communities remains a major analytical challenge. Here, we present a transferable supervised Raman imaging workflow that integrates spontaneous Raman spectroscopy, confocal Raman microscopy, and PCA-LDA chemometric analysis for the label-free identification of clinically relevant oral bacteria. The proposed framework uses Raman spectra acquired from isolated bacterial cells to train a supervised classifier that is directly transferred to hyperspectral Raman images, enabling quantitative pixel-wise bacterial identification without fluorescent labels or molecular probes. The workflow was validated using four representative oral bacterial species (Streptococcus oralis, Actinomyces naeslundii, Fusobacterium nucleatum, and Porphyromonas gingivalis), spanning the ecological transition from oral health to periodontal disease. The PCA-LDA classifier achieved 99.8% accuracy for binary classification, maintained an overall accuracy of 93.8% after extension to four bacterial species, and successfully identified P. gingivalis at bacterial ratios as low as 1:6000 within mixed populations. Importantly, the classifier, trained exclusively on planktonic single-cell Raman spectra, was directly transferred to Raman images of mixed bacterial communities and increasingly complex biofilm models without retraining, achieving classification accuracies of approximately 98%. The Raman-based classification was independently validated by morphology-based segmentation and Gram staining. These results establish a scalable and transferable analytical framework for quantitative Raman imaging of polymicrobial communities. By combining supervised machine learning with hyperspectral Raman microscopy, the proposed workflow provides a versatile strategy for label-free bacterial identification and spatial mapping, representing an important step toward Raman-based precision microbiology and future optical diagnostics of oral infectious diseases.
- 7 September 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessIntegrated Raman Spectroscopy and Supervised Imaging for Label-Free Identification and Mapping of Oral Pathogens in Complex Biofilms
Although Raman spectroscopy has demonstrated excellent performance for the identification of isolated bacterial cells, its application to spatially resolved analysis of complex polymicrobial communities remains a major analytical challenge. Here, we present a transferable supervised Raman imaging workflow that integrates spontaneous Raman spectroscopy, confocal Raman microscopy, and PCA-LDA chemometric analysis for the label-free identification of clinically relevant oral bacteria. The proposed framework uses Raman spectra acquired from isolated bacterial cells to train a supervised classifier that is directly transferred to hyperspectral Raman images, enabling quantitative pixel-wise bacterial identification without fluorescent labels or molecular probes. The workflow was validated using four representative oral bacterial species (Streptococcus oralis, Actinomyces naeslundii, Fusobacterium nucleatum, and Porphyromonas gingivalis), spanning the ecological transition from oral health to periodontal disease. The PCA-LDA classifier achieved 99.8% accuracy for binary classification, maintained an overall accuracy of 93.8% after extension to four bacterial species, and successfully identified P. gingivalis at bacterial ratios as low as 1:6000 within mixed populations. Importantly, the classifier, trained exclusively on planktonic single-cell Raman spectra, was directly transferred to Raman images of mixed bacterial communities and increasingly complex biofilm models without retraining, achieving classification accuracies of approximately 98%. The Raman-based classification was independently validated by morphology-based segmentation and Gram staining. These results establish a scalable and transferable analytical framework for quantitative Raman imaging of polymicrobial communities. By combining supervised machine learning with hyperspectral Raman microscopy, the proposed workflow provides a versatile strategy for label-free bacterial identification and spatial mapping, representing an important step toward Raman-based precision microbiology and future optical diagnostics of oral infectious diseases.
- 5 March 2026
- Published by SPIE-Intl Soc Optical Eng
Multifunctional biosilica nanoparticles for medicine
- 5 March 2026
- Published by SPIE-Intl Soc Optical Eng
Multifunctional biosilica nanoparticles for medicine
- 1 September 2025
- Published by Springer Nature
- p. 399-420
Applications of Raman Spectroscopy in Preclinical Bioimaging
- 1 September 2025
- Published by Springer Nature
- p. 399-420
Applications of Raman Spectroscopy in Preclinical Bioimaging
- Open Access
- 21 August 2025
- Published by Wiley in Advanced Science
- Vol. 12 (42) , e09420
Polarization‐Sensitive Holotomography for Multidimensional Label‐Free Imaging and Characterization of Lipid Droplets in Cancer Cells
Lipid droplets (LDs) are key markers of cellular metabolism, often altered in cancer. While holotomography enables 3D, label‐free imaging of LDs via refractive index, it relies on complex thresholding and lacks biochemical specificity. Here, polarization‐sensitive holotomography (PS‐HT), which leverages the intrinsic birefringence of LDs for high‐contrast, selective identification with a fixed near‐zero threshold is presented. Using prostate cell models (healthy PNT2 and cancer PC3), PS‐HT is validated against fluorescence microscopy and holotomography, showing that it enables accurate quantification of birefringence, LD volume, dry mass, molecular organization, and spatial distribution. Cancer cells show significantly higher birefringence after glucose treatment, reflecting enhanced lipid accumulation. PS‐HT, combined with principal component analysis, achieves near‐perfect classification of cancer versus healthy cells, establishing it as a robust, label‐free tool for studying lipid metabolism and cancer diagnostics.
- 21 August 2025
- Published by Wiley in Advanced Science
- Vol. 12 (42) , e09420
Open AccessPolarization‐Sensitive Holotomography for Multidimensional Label‐Free Imaging and Characterization of Lipid Droplets in Cancer Cells
Lipid droplets (LDs) are key markers of cellular metabolism, often altered in cancer. While holotomography enables 3D, label‐free imaging of LDs via refractive index, it relies on complex thresholding and lacks biochemical specificity. Here, polarization‐sensitive holotomography (PS‐HT), which leverages the intrinsic birefringence of LDs for high‐contrast, selective identification with a fixed near‐zero threshold is presented. Using prostate cell models (healthy PNT2 and cancer PC3), PS‐HT is validated against fluorescence microscopy and holotomography, showing that it enables accurate quantification of birefringence, LD volume, dry mass, molecular organization, and spatial distribution. Cancer cells show significantly higher birefringence after glucose treatment, reflecting enhanced lipid accumulation. PS‐HT, combined with principal component analysis, achieves near‐perfect classification of cancer versus healthy cells, establishing it as a robust, label‐free tool for studying lipid metabolism and cancer diagnostics.
- 9 August 2025
- Published by Elsevier in Food Chemistry
- Vol. 493 (Pt 4) , 145890
Engineering gold nanoparticles aggregation in acrylate hydrogel-photopolymers for SERS-based on-site highly sensitive dimethoate detection on olives
- 9 August 2025
- Published by Elsevier in Food Chemistry
- Vol. 493 (Pt 4) , 145890
Engineering gold nanoparticles aggregation in acrylate hydrogel-photopolymers for SERS-based on-site highly sensitive dimethoate detection on olives
- Open Access
- 6 August 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-13
TGF-β1-mediated downregulation of L1CAM in pancreatic ductal adenocarcinoma drives upregulation of collagen 17A1 and MMP2, facilitating tumor invasiveness and metastasis
The highly fibrotic microenvironment of pancreatic ductal adenocarcinoma (PDAC) poses significant challenges for effective treatment, particularly in drug delivery and tumor progression. Our study investigates the role of collagen dynamics in PDAC, revealing that TGF-β1 negatively regulates the expression of L1 cell adhesion molecule (L1CAM), leading to a more invasive tumor phenotype. We identify a subset of PDAC cells with low L1CAM expression (L1low) that actively influences collagen deposition and remodeling, as evidenced by the upregulation of collagen 17A1 (COL17A1) and matrix metalloproteinase 2 (MMP2), both associated with poor prognosis. In vivo studies demonstrate that L1low cells correlate with increased collagen deposition, reduced sensitivity to gemcitabine, and heightened liver metastasis. The secretion of COL17A1 and MMP2 by these cells enhances their migratory capabilities and contributes to the formation of a fibrotic stroma that facilitates tumor progression. This interaction underscores the critical role of collagen in shaping the tumor microenvironment and promoting aggressive tumor behavior. Notably, treatment with Tranilast significantly reduced collagen deposition and MMP2 levels while promoting L1CAM expression, suggesting a therapeutic avenue for counteracting the aggressive characteristics of L1low cells. By modulating collagen dynamics and enhancing drug delivery, Tranilast may improve treatment outcomes for patients with low L1CAM-expressing tumors. Understanding the mechanisms by which L1low cells contribute to collagen secretion and tumor aggressiveness is essential for developing effective interventions in pancreatic cancer.
- 6 August 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-13
Open AccessTGF-β1-mediated downregulation of L1CAM in pancreatic ductal adenocarcinoma drives upregulation of collagen 17A1 and MMP2, facilitating tumor invasiveness and metastasis
The highly fibrotic microenvironment of pancreatic ductal adenocarcinoma (PDAC) poses significant challenges for effective treatment, particularly in drug delivery and tumor progression. Our study investigates the role of collagen dynamics in PDAC, revealing that TGF-β1 negatively regulates the expression of L1 cell adhesion molecule (L1CAM), leading to a more invasive tumor phenotype. We identify a subset of PDAC cells with low L1CAM expression (L1low) that actively influences collagen deposition and remodeling, as evidenced by the upregulation of collagen 17A1 (COL17A1) and matrix metalloproteinase 2 (MMP2), both associated with poor prognosis. In vivo studies demonstrate that L1low cells correlate with increased collagen deposition, reduced sensitivity to gemcitabine, and heightened liver metastasis. The secretion of COL17A1 and MMP2 by these cells enhances their migratory capabilities and contributes to the formation of a fibrotic stroma that facilitates tumor progression. This interaction underscores the critical role of collagen in shaping the tumor microenvironment and promoting aggressive tumor behavior. Notably, treatment with Tranilast significantly reduced collagen deposition and MMP2 levels while promoting L1CAM expression, suggesting a therapeutic avenue for counteracting the aggressive characteristics of L1low cells. By modulating collagen dynamics and enhancing drug delivery, Tranilast may improve treatment outcomes for patients with low L1CAM-expressing tumors. Understanding the mechanisms by which L1low cells contribute to collagen secretion and tumor aggressiveness is essential for developing effective interventions in pancreatic cancer.
- Open Access
- 28 July 2025
- Published by Elsevier in Sensors and Actuators Reports
- Vol. 10
PNA-SERS biosensor for label-free detection of SARS-CoV-2 genomic sequences in saliva
- 28 July 2025
- Published by Elsevier in Sensors and Actuators Reports
- Vol. 10
Open AccessPNA-SERS biosensor for label-free detection of SARS-CoV-2 genomic sequences in saliva
- Open Access
- 1 November 2024
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 19, 12079-12098
Hybrid Biosilica Nanoparticles for in-vivo Targeted Inhibition of Colorectal Cancer Growth and Label-Free Imaging
Background: Metastasis-initiating cells are key players in progression, resistance, and relapse of colorectal cancer (CRC), by leveraging the regulatory relationship between Transforming Growth Factor-beta (TGF-β) signaling and anti-L1 cell adhesion molecule (L1CAM). Methods: This study introduces a novel strategy for CRC targeted therapy and imaging based on the use of a hybrid nanosystem made of gold nanoparticles-covered porous biosilica further modified with the (L1CAM) antibody. Results: The nanosystem intracellularly delivers galunisertib (LY), a TGF-β inhibitor, aiming to inhibit epithelial-mesenchymal transition (EMT), a process pivotal for metastasis. Anti-L1CAM antibody-functionalized nanoparticles (NPs) target tumor-initiating cells expressing L1CAM, inhibiting cancer growth. The number of antibody molecules conjugated to the single NP is precisely quantified, revealing a high surface coverage that facilitates the tumor targeting. The therapeutic efficacy of the nanosystem is investigated in organoid-like cultures of CRC cells and in vivo mouse models, showing a significant reduction in tumor growth. The spatial distribution of NPs within CRC tumors from mice is investigated using a label-free optical approach based on Raman micro-spectroscopy. Conclusion: This research highlights the multifunctional capabilities of engineered biosilica NPs, which offer new insights in targeted CRC therapy and imaging, improving patient outcomes and paving the way for personalized therapies.
- 1 November 2024
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 19, 12079-12098
Open AccessHybrid Biosilica Nanoparticles for in-vivo Targeted Inhibition of Colorectal Cancer Growth and Label-Free Imaging
Background: Metastasis-initiating cells are key players in progression, resistance, and relapse of colorectal cancer (CRC), by leveraging the regulatory relationship between Transforming Growth Factor-beta (TGF-β) signaling and anti-L1 cell adhesion molecule (L1CAM). Methods: This study introduces a novel strategy for CRC targeted therapy and imaging based on the use of a hybrid nanosystem made of gold nanoparticles-covered porous biosilica further modified with the (L1CAM) antibody. Results: The nanosystem intracellularly delivers galunisertib (LY), a TGF-β inhibitor, aiming to inhibit epithelial-mesenchymal transition (EMT), a process pivotal for metastasis. Anti-L1CAM antibody-functionalized nanoparticles (NPs) target tumor-initiating cells expressing L1CAM, inhibiting cancer growth. The number of antibody molecules conjugated to the single NP is precisely quantified, revealing a high surface coverage that facilitates the tumor targeting. The therapeutic efficacy of the nanosystem is investigated in organoid-like cultures of CRC cells and in vivo mouse models, showing a significant reduction in tumor growth. The spatial distribution of NPs within CRC tumors from mice is investigated using a label-free optical approach based on Raman micro-spectroscopy. Conclusion: This research highlights the multifunctional capabilities of engineered biosilica NPs, which offer new insights in targeted CRC therapy and imaging, improving patient outcomes and paving the way for personalized therapies.
- Open Access
- 31 October 2024
- Published by EDP Sciences in EPJ Web of Conferences
- Vol. 309, 10020
Intracellular delivery, imaging and drug-sensing using a plasmonic-enhanced hybrid nanostystem
Metastasis stands as the leading cause of mortality among colorectal cancer (CRC) patients. Galunisertib (LY2157299, LY) is a small molecule demonstrating promising anti-cancer effects by targeting the Transforming Growth Factor-beta (TGF-β) pathway. This route plays a pivotal role in initiating the epithelial-to-mesenchymal transition (EMT), a critical process for metastatic spread. Unfortunately, LY chronic treatment causes undesired effects. To mitigate these side effects, nanoscale drug delivery systems have emerged as a transformative approach in cancer treatment, enhancing drug effectiveness while minimizing toxicity. In this study, we introduce a hybrid nanosystem (DNP-AuNPs-LY@Gel) comprising porous diatomite nanoparticles decorated with plasmonic gold nanoparticles (AuNPs), encapsulating LY within a gelatin shell. This multifunctional nanosystem demonstrates efficient LY delivery, EMT reversal in CRC 2D and 3D cultures, and anti-cancer effects in vivo. Moreover, the nanosystem allowed the quantification with sub-femtogram resolution of the drug intracellularly released using surface-enhanced Raman spectroscopy (SERS). The release of LY is triggered by CRC cell acidic microenviroment. Real-time monitoring of drug release at the single-cell level is achieved by analyzing SERS signals of LY within CRC cells. The heightened efficacy of LY delivery through the DNP-AuNPs-LY@Gel complex offers a promising alternative strategy for reducing drug dosages and subsequent undesired effects.
- 31 October 2024
- Published by EDP Sciences in EPJ Web of Conferences
- Vol. 309, 10020
Open AccessIntracellular delivery, imaging and drug-sensing using a plasmonic-enhanced hybrid nanostystem
Metastasis stands as the leading cause of mortality among colorectal cancer (CRC) patients. Galunisertib (LY2157299, LY) is a small molecule demonstrating promising anti-cancer effects by targeting the Transforming Growth Factor-beta (TGF-β) pathway. This route plays a pivotal role in initiating the epithelial-to-mesenchymal transition (EMT), a critical process for metastatic spread. Unfortunately, LY chronic treatment causes undesired effects. To mitigate these side effects, nanoscale drug delivery systems have emerged as a transformative approach in cancer treatment, enhancing drug effectiveness while minimizing toxicity. In this study, we introduce a hybrid nanosystem (DNP-AuNPs-LY@Gel) comprising porous diatomite nanoparticles decorated with plasmonic gold nanoparticles (AuNPs), encapsulating LY within a gelatin shell. This multifunctional nanosystem demonstrates efficient LY delivery, EMT reversal in CRC 2D and 3D cultures, and anti-cancer effects in vivo. Moreover, the nanosystem allowed the quantification with sub-femtogram resolution of the drug intracellularly released using surface-enhanced Raman spectroscopy (SERS). The release of LY is triggered by CRC cell acidic microenviroment. Real-time monitoring of drug release at the single-cell level is achieved by analyzing SERS signals of LY within CRC cells. The heightened efficacy of LY delivery through the DNP-AuNPs-LY@Gel complex offers a promising alternative strategy for reducing drug dosages and subsequent undesired effects.